as 07-26-2024 4:00pm EST
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Upcoming Earnings Alert:
Get ready for potential market movements as GSK plc (Each representing two) GSK prepares to release earnings report on 31 Jul 2024.
Founded: | 1715 | Country: | United Kingdom |
Employees: | N/A | City: | N/A |
Market Cap: | 78.9B | IPO Year: | N/A |
Target Price: | $48.00 | AVG Volume (30 days): | 2.7M |
Analyst Decision: | Buy | Number of Analysts: | 5 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 2.81 | EPS Growth: | -69.52 |
52 Week Low/High: | $33.67 - $45.93 | Next Earning Date: | 07-31-2024 |
Revenue: | $39,410,256,410 | Revenue Growth: | 5.69% |
Revenue Growth (this year): | 7.74% | Revenue Growth (next year): | 6.34% |
GSK Breaking Stock News: Dive into GSK Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Motley Fool
9 days ago
Argus Research
10 days ago
Argus Research
10 days ago
Business Wire
15 days ago
Pharmaceutical Technology
17 days ago
Insider Monkey
18 days ago
Benzinga
18 days ago
The information presented on this page, "GSK GSK plc (Each representing two) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.